Triumvira Immunologics to Present Claudin 18.2 Phase 1 Study Data at SITC Annual Meeting

Triumvira Immunologics, a clinical-stage firm focused on developing advanced T cell therapies for solid tumors, revealed that Dr. Ecaterina E. Dumbrava from The University of Texas MD Anderson Cancer Center will present new research findings at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event is scheduled to take place in Houston, Texas, from November 6-10, 2024. Dr. Dumbrava's presentation will feature crucial interim data from Triumvira's Phase 1/2 clinical trial, TACTIC-3, centered on the TAC101-CLDN18.2 T cell therapy aimed at treating Claudin 18.2+ advanced solid tumors.

The TACTIC-3 trial is exploring the safety and efficacy of TAC101-CLDN18.2, an innovative T cell therapy that targets Claudin 18.2+ solid tumors. This therapy utilizes Triumvira's exclusive T cell Antigen Coupler (TAC) technology, which enhances the natural functions of T cells to fight solid tumors safely and effectively.

Robert Williamson, President of Triumvira Immunologics, expressed enthusiasm about sharing the early positive results from the TACTIC-3 trial at the SITC conference. He emphasized that their approach takes advantage of the body's immune system to target challenging cancers like Claudin 18.2+ solid tumors. Williamson believes this milestone marks significant progress in their mission to create next-generation cell therapies capable of transforming the treatment landscape for patients battling difficult-to-treat cancers.

The abstract presentation, numbered 1472, is entitled "A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors." Alongside Dr. Dumbrava, the authors include Syma Iqbal, Simon Turcotte, Gregory Botta, Benjamin Schlechter, Geoffrey Ku, Peter Hosein, Sam Saibil, Miriam Gavriliuc, Maria Apostolopoulou, Mobolaji Giwa, Kara Moss, Swaminathan Murugappan, and Davendra Sohal. The session, "Biotech Breakthroughs – Solid Tumor IO at the Tipping Point," will be held on Friday, November 8, 2024, between 1:45 p.m. and 3:20 p.m. CDT.

The TACTIC-3 trial (NCT05862324) is the first of its kind, designed to evaluate the safety, recommended Phase II dose (RP2D), pharmacokinetics, and efficacy of TAC101-CLDN18.2 in patients with Claudin 18.2+ solid tumors who have previously undergone two or more lines of therapy (one prior line of therapy for patients with pancreatic tumors). The trial encompasses subjects with advanced gastric and other solid tumors expressing Claudin 18.2, offering the potential to address significant unmet medical needs in oncology.

Triumvira Immunologics is at the forefront of clinical-stage solid tumor cell therapy, developing unique, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat solid tumor patients. Their proprietary TAC technology platform activates natural T cell functions differently from other cell therapies, like CAR-T and engineered T cell receptor (TCR) therapies, leading to clinically safe, effective, and re-dosable cell therapies. Triumvira's pipeline targets promising tumor-associated antigens, including Claudin 18.2, HER2, GUCY2C, and GPC3. The company operates in San Diego, CA, Austin, Texas, and Hamilton, Ontario.